QUEST DIAGNOSTICS INC vs VERACYTE, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Veracyte earns the fatter margins, 16.3% operating against Quest's 13.8%, with a 72.7% gross margin that towers over routine-lab economics, and the market pays accordingly: 56 times earnings against 23.2. The scale gap runs the other way, $23B of Quest against $5B of Veracyte, network volume against specialized genomic tests. Quest converts more of its price into cash, 5.6% against 3.2%, and pays the only dividend; Veracyte holds a 9.3 current ratio war chest with no debt. Returns on assets nearly tie at 6.1%. The premium multiple buys menu growth and margin structure; the discount buys distribution and dividends. Specialization is currently priced at well over twice the rate of scale.
Comparison updated 2026-07-10.
| Metric | DGX | VCYT |
|---|---|---|
| Price | $209.79 | $60.46 |
| Market cap | $23.5B | $4.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Mature | Growth |
| Implied growth (priced in) | -3.3% | — |
| P/E | 23.2 | 56.0 |
| P/B | 3.07 | 3.66 |
| P/S | 2.08 | 9.07 |
| EV/EBITDA | 10.8 | 56.1 |
| Revenue growth | +11.2% | +16.9% |
| Gross margin | — | 72.7% |
| Operating margin | 13.8% | 16.3% |
| Net margin | 9.1% | 16.3% |
| Return on equity | 13.4% | 6.5% |
| Return on assets | 6.1% | 6.1% |
| Return on invested capital | 15.6% | 5.5% |
| FCF yield | 5.6% | 3.2% |
| Dividend yield | 0.9% | — |
| Debt / equity | 0.07 | 0.00 |
| Current ratio | 1.18 | 9.31 |
| Altman Z (solvency) | 7.64 | 6.48 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.